Chemicals and compounds that have been seen to cause cherry angiomas are mustard gas, 2-butoxyethanol, bromides, and cyclosporine.A significant increase in the density of mast cells has been seen in cherry hemangiomas compared with normal skin. Diagnosis
The diagnosis is based on the clinical appearance of the lesions. Examination with a dermatoscope shows characteristic red, purple, or blue-black lagoons. The differential diagnosis includes nodular basal cell carcinoma, amelanotic melanoma, and angiokeratoma. Treatment
These lesions generally do not require treatment. If they are cosmetically unappealing or are subject to bleeding angiomas may be removed by electrocautery, a process of destroying the tissue by use of a small probe with an electric current running through it. Removal may cause scarring. More recently pulsed dye laser or intense pulsed light (IPL) treatment has also been used.Future treatment based on a locally acting inhibitor of MEK1 and Cyclin E1 could possibly be an option. A natural MEK1 inhibitor is myricetin. Prognosis
In most patients, the number and size of cherry angiomas increases with advancing age. They are harmless, having no relation to cancer at all. Eruptive cherry hemangiomatosis, has been rarely reported as a heralding sign of multicentric Castleman disease (MCD), multiple myeloma and other lymphoproliferative diseases. Epidemiology
Cherry angiomas occur in all races, ethnic backgrounds, and sexes. References
External links

eMedicine with picture showing small red dots
Pereira, José Marcos (2004). "Hemangioma rubi no couro cabeludo". Anais Brasileiros de Dermatologia. 79: 83–89. doi:10.1590/S0365-05962004000100010.
Raxibacumab  is a human monoclonal antibody intended for the prophylaxis and treatment of inhaled anthrax. Its efficacy has been proven in rabbits and monkeys. In December 2012 raxibacumab was approved in the United States for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.The antibody was discovered in a joint venture between Cambridge Antibody Technology and Human Genome Sciences. Cambridge Antibody Technology discovered the antibody to Human Genome Sciencess target and, in 2012, HGS were purchased by GlaxoSmithKline (GSK). In 2017, it was acquired by Emergent BioSolutions

Side effects
The most commonly observed adverse events are headaches, upper respiratory tract infection, nausea, pain in extremity and pruritus skin itching. Pharmacology
Raxibacumab injection is a monoclonal antibody targeting the protective antigen (PA) component of the lethal toxin of Bacillus anthracis. Development history
Raxibacumab was developed by Human Genome Sciences (HGS) in conjunction with the U.S. Department of Health and Human Services (HHS) under contract number HHS010020050006C. At the 2 November 2012 meeting of the Anti-Infective Drugs Advisory Committee to the US Food and Drug Administration (FDA) members "voted 16 to 1 in support of the clinical benefit of raxibacumab for the treatment of inhalational anthrax, with one abstention. In addition, the committee voted 18 – 0 in favour of the risk-benefit profile of raxibacumab". In 2009, support from the FDA was denied after it "expressed doubt on the agents added benefit over the antibiotic levofloxacin (Levaquin) alone".